Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/469
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorRODRIGUES, C. E. M.-
dc.contributor.authorVENDRAMINI, M. B.-
dc.contributor.authorBUENO, C.-
dc.contributor.authorBONFA, E.-
dc.contributor.authorCARVALHO, J. F. de-
dc.date.accessioned2013-07-30T14:41:52Z-
dc.date.available2013-07-30T14:41:52Z-
dc.date.issued2012-
dc.identifier.citationCLINICAL AND EXPERIMENTAL RHEUMATOLOGY, v.30, n.6, p.871-878, 2012-
dc.identifier.issn0392-856X-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/469-
dc.description.abstractObjective This study was undertaken to evaluate a possible association of adipocytokines with metabolic syndrome (MetS), inflammation and other cardiovascular risk factors in primary antiphospholipid syndrome (PAPS). Methods Fifty-six PAPS patients and 72 controls were included. Adiponectin, leptin, visfatin, resistin, plasminogen activator inhibitor-1 (PAI-1), lipoprotein (a), glucose, ESR, CRP, uric acid and lipid profiles were measured. The presence of MetS was determined as defined by the International Diabetes Federation (IDF), and insulin resistance was rated using the homeostasis model assessment (HOMA) index. Results Concentrations of leptin were higher [21.5 (12.9-45.7) ng/mL] in PAPS patients than in the controls ([2.1 (6.9-26.8) ng/mL), p=0.001]. In PAPS patients, leptin and PAI-1 levels were positively correlated with BMI (r=0.61 and 0.29), HOMA-IR (r=0.71 and 0.28) and CRP (r=0.32 and 0.36). Adiponectin levels were negatively correlated with BMI (r=-0.28), triglycerides (r=-0.43) and HOMA-IR (r=-0.36) and positively correlated with HDL-c (r=0.37) and anti-beta 2GPI IgG (r=0.31). The presence of MetS in PAPS patients was associated with higher levels of leptin (p=0.002) and PAI-1 (p=0.03) levels and lower levels of adiponectin (p=0.042). Variables that independently influenced the adiponectin concentration were the triglyceride levels (p<0.001), VLDL-c (P=0.002) and anti-beta 2GPI IgG (p=0.042); the leptin levels were BMI (p<0.001), glucose (p=0.046), HOMA-IR (p<0.001) and ESR (p=0.006); and the PAI-1 levels were CRP (p=0.013) and MetS (p=0.048). Conclusion This study provides evidence that adipocytokines may be involved in low-grade inflammation, insulin resistance and MetS in PAPS patients.-
dc.description.sponsorshipFederico Foundation-
dc.description.sponsorshipFAPESP [2009/14784-8]-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [300665/2009-1, 301411/2009-3]-
dc.language.isoeng-
dc.publisherCLINICAL & EXPER RHEUMATOLOGY-
dc.relation.ispartofClinical and Experimental Rheumatology-
dc.rightsrestrictedAccess-
dc.subjectadipocytokines-
dc.subjectinflammation-
dc.subjectinsulin resistance-
dc.subjectmetabolic syndrome-
dc.subjectprimary antiphospholipid syndrome-
dc.subject.othersystemic-lupus-erythematosus-
dc.subject.otherdensity lipoprotein cholesterol-
dc.subject.otherrheumatoid-arthritis-
dc.subject.othercoronary atherosclerosis-
dc.subject.otherrisk-factors-
dc.subject.otheradiponectin concentrations-
dc.subject.othercardiovascular-disease-
dc.subject.otherconsensus statement-
dc.subject.otherplasma adiponectin-
dc.subject.otherleptin-
dc.titleAdipocytokines in primary antiphospholipid syndrome: potential markers of low-grade inflammation, insulin resistance and metabolic syndrome-
dc.typearticle-
dc.rights.holderCopyright CLINICAL & EXPER RHEUMATOLOGY-
dc.identifier.pmid22935544-
dc.subject.wosRheumatology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage871-
hcfmusp.description.endpage878-
hcfmusp.description.issue6-
hcfmusp.description.volume30-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000314002600010-
hcfmusp.origem.id2-s2.0-84871666488-
hcfmusp.publisher.cityPISA-
hcfmusp.publisher.countryITALY-
hcfmusp.relation.referenceAlberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x-
hcfmusp.relation.referenceAlessi MC, 2006, ARTERIOSCL THROM VAS, V26, P2200, DOI 10.1161/01.ATV.0000242905.41404.68-
hcfmusp.relation.referenceAmes PRJ, 2010, LUPUS, V19, P711, DOI 10.1177/0961203309357765-
hcfmusp.relation.referenceAmes PRJ, 2008, RHEUMATOLOGY, V47, P1832, DOI 10.1093/rheumatology/ken382-
hcfmusp.relation.referenceAmes PRJ, 2009, J THROMB HAEMOST, V7, P537, DOI 10.1111/j.1538-7836.2009.03308.x-
hcfmusp.relation.referenceChu NF, 2001, ATHEROSCLEROSIS, V157, P495, DOI 10.1016/S0021-9150(00)00755-3-
hcfmusp.relation.referenceChung CP, 2007, ANN RHEUM DIS, V66, P208, DOI 10.1136/ard.2006.054973-
hcfmusp.relation.referenceChung CP, 2009, LUPUS, V18, P799, DOI 10.1177/0961203309103582-
hcfmusp.relation.referenceCicero AFG, 2011, J ENDOCRINOL INVEST, V34, pE158, DOI 10.3275/7407-
hcfmusp.relation.referenceCugno M, 2010, J AUTOIMMUN, V34, P105, DOI 10.1016/j.jaut.2009.07.004-
hcfmusp.relation.referencede Groot PG, 2008, SEMIN THROMB HEMOST, V34, P347, DOI 10.1055/s-0028-1085477-
hcfmusp.relation.referenceDe Mitrio V, 1999, METABOLISM, V48, P960, DOI 10.1016/S0026-0495(99)90190-7-
hcfmusp.relation.referenceDerdemezis CS, 2011, CLIN EXP RHEUMATOL, V29, P712-
hcfmusp.relation.referenceDomali E, 2002, J Matern Fetal Neonatal Med, V12, P222, DOI 10.1080/jmf.12.4.222.230-
hcfmusp.relation.referenceCleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486-
hcfmusp.relation.referenceFANTUZZI G, 2004, J ALLERGY CLIN IMMUN, V23, P416-
hcfmusp.relation.referenceFOSSATI P, 1982, CLIN CHEM, V28, P2077-
hcfmusp.relation.referenceFRIEDEWA.WT, 1972, CLIN CHEM, V18, P499-
hcfmusp.relation.referenceGiannakopoulos B, 2007, BLOOD, V109, P422, DOI 10.1182/blood-2006-04-001206-
hcfmusp.relation.referenceGuzik TJ, 2006, J PHYSIOL PHARMACOL, V57, P505-
hcfmusp.relation.referenceHaris EN, 1994, AM J CLIN PATHOL, V101, P616-
hcfmusp.relation.referenceKater ALD, 2010, METABOLISM, V59, P921, DOI 10.1016/j.metabol.2010.02.011-
hcfmusp.relation.referenceLago F, 2007, CYTOKINE GROWTH F R, V18, P313, DOI 10.1016/j.cytogfr.2007.04.007-
hcfmusp.relation.referenceLaumen H, 2008, ATHEROSCLEROSIS, V196, P565, DOI 10.1016/j.atherosclerosis.2007.06.005-
hcfmusp.relation.referenceLaurberg TB, 2009, J RHEUMATOL, V36, P1885, DOI 10.3899/jrheum.080907-
hcfmusp.relation.referenceLOPEZ-PEDRERA C, 2008, ARTHRITIS RHEUM, V58, P2853-
hcfmusp.relation.referenceMaahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5-
hcfmusp.relation.referenceMartin SS, 2008, J AM COLL CARDIOL, V52, P1201, DOI 10.1016/j.jacc.2008.05.060-
hcfmusp.relation.referenceMatsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF-
hcfmusp.relation.referenceMedina G, 2011, AUTOIMMUN REV, V10, P214, DOI 10.1016/j.autrev.2010.10.004-
hcfmusp.relation.referenceMedina G, 2003, ANN RHEUM DIS, V62, P607, DOI 10.1136/ard.62.7.607-
hcfmusp.relation.referenceMiyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x-
hcfmusp.relation.referenceMiyazaki Y, 2008, DIABETES OBES METAB, V10, P1204, DOI 10.1111/j.1463-1326.2008.00880.x-
hcfmusp.relation.referencePopa C, 2009, J RHEUMATOL, V36, P724, DOI 10.3899/jrheum.080626-
hcfmusp.relation.referenceRamsay JE, 2003, HYPERTENSION, V42, P891, DOI 10.1161/01.HYP.0000095981.92542.F6-
hcfmusp.relation.referenceReilly MP, 2004, CIRCULATION, V110, P803, DOI 10.1161/01.CIR.0000138740.84883.9C-
hcfmusp.relation.referenceReilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0-
hcfmusp.relation.referenceRho YH, 2010, ARTHRITIS RHEUM-US, V62, P1259, DOI 10.1002/art.27376-
hcfmusp.relation.referenceRuffatti A, 2011, ANN RHEUM DIS, V70, P1083, DOI 10.1136/ard.2010.142042-
hcfmusp.relation.referenceSacre K, 2010, ARTHRITIS RHEUM-US, V62, P2093, DOI 10.1002/art.27488-
hcfmusp.relation.referenceSada KE, 2006, J RHEUMATOL, V33, P1545-
hcfmusp.relation.referenceSchalkwijk CG, 2006, THROMB HAEMOSTASIS, V96, P698, DOI 10.1160/06-11-0631-
hcfmusp.relation.referenceShoenfeld Y, 2005, CIRCULATION, V112, P3337, DOI 10.1161/CIRCULATIONHA.104.507996-
hcfmusp.relation.referenceSIEDEL J, 1983, CLIN CHEM, V29, P1075-
hcfmusp.relation.referenceSkurk T, 2002, HORM METAB RES, V34, P659, DOI 10.1055/s-2002-38253-
hcfmusp.relation.referenceSun YM, 2010, PEPTIDES, V31, P1205, DOI 10.1016/j.peptides.2010.03.023-
hcfmusp.relation.referenceUrbanus RT, 2009, LANCET NEUROL, V8, P998, DOI 10.1016/S1474-4422(09)70239-X-
hcfmusp.relation.referenceWARNICK GR, 1979, CLIN CHEM, V25, P596-
hcfmusp.relation.referenceWhitehead JP, 2006, DIABETES OBES METAB, V8, P264, DOI 10.1111/j.1463-1326.2005.00510.x-
hcfmusp.relation.referenceWisloff F, 2002, THROMB RES, V108, P263, DOI 10.1016/S0049-3848(02)00400-0-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipCNPq-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.remissive.sponsorshipFederico Foundation-
hcfmusp.remissive.sponsorshipCNPq-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.remissive.sponsorshipFederico Foundation-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus15-
hcfmusp.scopus.lastupdate2022-05-20-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia


Files in This Item:
File Description SizeFormat 
art_RODRIGUES_Adipocytokines_in_primary_antiphospholipid_syndrome_potential_markers_of_2012.PDF
  Restricted Access
publishedVersion (English)552.18 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.